guardian pharmacy services inc - GRDN

GRDN

Close Chg Chg %
31.29 -0.39 -1.25%

Closed Market

30.90

-0.39 (1.25%)

Volume: 79.43K

Last Updated:

Dec 24, 2025, 12:59 PM EDT

Company Overview: guardian pharmacy services inc - GRDN

GRDN Key Data

Open

$31.11

Day Range

30.58 - 31.11

52 Week Range

17.91 - 37.43

Market Cap

$1.98B

Shares Outstanding

63.32M

Public Float

22.49M

Beta

0.96

Rev. Per Employee

N/A

P/E Ratio

48.48

EPS

$0.64

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

289.28K

 

GRDN Performance

1 Week
 
-2.16%
 
1 Month
 
5.40%
 
3 Months
 
18.65%
 
1 Year
 
45.50%
 
5 Years
 
N/A
 

GRDN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About guardian pharmacy services inc - GRDN

Guardian Pharmacy Services, Inc. engages in the provision of client service and resident care to long-term care communities. It offers assisted living and skilled nursing, group homes, behavioral health and organizations that serve individuals with intellectual and developmental disabilities. The company was founded by Fred Burke, David Morris, and Kendall Forbes on July 21, 2003 and is headquartered in Atlanta, GA.

GRDN At a Glance

Guardian Pharmacy Services, Inc.
300 Galleria Parkway SE
Atlanta, Georgia 30339
Phone 1-404-810-0089 Revenue 1.23B
Industry Drugstore Chains Net Income -110,047,000.00
Sector Retail Trade 2024 Sales Growth 17.417%
Fiscal Year-end 12 / 2025 Employees 3,400
View SEC Filings

GRDN Valuation

P/E Current 48.484
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.044
Price to Book Ratio 8.987
Price to Cash Flow Ratio 22.12
Enterprise Value to EBITDA -30.643
Enterprise Value to Sales 1.076
Total Debt to Enterprise Value 0.028

GRDN Efficiency

Revenue/Employee 361,296.765
Income Per Employee -32,366.765
Receivables Turnover 12.644
Total Asset Turnover 4.051

GRDN Liquidity

Current Ratio 1.055
Quick Ratio 0.773
Cash Ratio 0.032

GRDN Profitability

Gross Margin 19.127
Operating Margin -5.122
Pretax Margin -5.412
Net Margin -8.958
Return on Assets -36.291
Return on Equity -128.80
Return on Total Capital -61.136
Return on Invested Capital -90.678

GRDN Capital Structure

Total Debt to Total Equity 26.166
Total Debt to Total Capital 20.74
Total Debt to Total Assets 11.134
Long-Term Debt to Equity 18.723
Long-Term Debt to Total Capital 14.84
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Guardian Pharmacy Services Inc - GRDN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
792.07M 908.91M 1.05B 1.23B
Sales Growth
- +14.75% +15.10% +17.42%
Cost of Goods Sold (COGS) incl D&A
638.14M 730.50M 846.54M 993.45M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.53M 16.56M 18.23M 19.77M
Depreciation
12.99M 13.20M 15.17M 16.47M
Amortization of Intangibles
3.54M 3.37M 3.07M 3.30M
COGS Growth
- +14.47% +15.88% +17.35%
Gross Income
153.93M 178.40M 199.65M 234.96M
Gross Income Growth
- +15.90% +11.91% +17.69%
Gross Profit Margin
+19.43% +19.63% +19.08% +19.13%
2021 2022 2023 2024 5-year trend
SG&A Expense
123.78M 126.41M 158.71M 297.88M
Research & Development
- - - -
-
Other SG&A
123.78M 126.41M 158.71M 297.88M
SGA Growth
- +2.13% +25.54% +87.69%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
30.15M 51.99M 40.95M (62.92M)
Non Operating Income/Expense
(187.00K) (403.00K) (367.00K) (279.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.64M 1.93M 2.86M 3.28M
Interest Expense Growth
- +17.65% +48.44% +14.66%
Gross Interest Expense
1.64M 1.93M 2.86M 3.28M
Interest Capitalized
- - - -
-
Pretax Income
28.33M 49.66M 37.72M (66.48M)
Pretax Income Growth
- +75.32% -24.05% -276.24%
Pretax Margin
+3.58% +5.46% +3.61% -5.41%
Income Tax
- - - 4.56M
-
Income Tax - Current - Domestic
- - - 3.85M
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 701.00K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
28.33M 49.66M 37.72M (71.03M)
Minority Interest Expense
12.01M 14.24M 13.82M 39.01M
Net Income
16.31M 35.42M 23.90M (110.05M)
Net Income Growth
- +117.12% -32.52% -560.41%
Net Margin Growth
+2.06% +3.90% +2.28% -8.96%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
16.31M 35.42M 23.90M (110.05M)
Preferred Dividends
- - - -
-
Net Income Available to Common
16.31M 35.42M 23.90M (110.05M)
EPS (Basic)
0.2627 0.5704 0.3849 -1.7388
EPS (Basic) Growth
- +117.13% -32.52% -551.75%
Basic Shares Outstanding
62.09M 62.09M 62.09M 63.29M
EPS (Diluted)
0.2627 0.5704 0.3849 -1.7388
EPS (Diluted) Growth
- +117.13% -32.52% -551.75%
Diluted Shares Outstanding
62.09M 62.09M 62.09M 63.29M
EBITDA
46.68M 68.55M 59.18M (43.15M)
EBITDA Growth
- +46.86% -13.67% -172.91%
EBITDA Margin
+5.89% +7.54% +5.66% -3.51%

Snapshot

Average Recommendation BUY Average Target Price 33.00
Number of Ratings 4 Current Quarters Estimate 0.268
FY Report Date 12 / 2025 Current Year's Estimate 0.983
Last Quarter’s Earnings 0.25 Median PE on CY Estimate N/A
Year Ago Earnings -1.77 Next Fiscal Year Estimate 1.078
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.27 0.24 0.98 1.08
High Estimates 0.28 0.25 1.01 1.14
Low Estimate 0.26 0.23 0.96 1.03
Coefficient of Variance 3.58 4.03 2.10 4.31

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Guardian Pharmacy Services Inc - GRDN

Date Name Shares Transaction Value
Apr 2, 2025 Cardinal Equity Partners LLC Director 471,057 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 David Morris See Remarks; Director 652,254 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Fred Burke See Remarks; Director 1,298,826 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Kendall Forbes See Remarks 618,955 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Pharmacy Investments, L.L.C. Director 1,413,940 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Bindley Capital Partners I LLC Director 6,100,176 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Guardian Pharmacy Services Inc in the News